Status:
UNKNOWN
Aspergillosis and Humoral Alveolar Immunity by Proteomics
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Aspergillus Fumigatus Infection
Eligibility:
All Genders
18+ years
Brief Summary
Aspergillus fumigatus is the most common opportunistic mold found in lung fungal infections in humans. Aspergillus is the cause of invasive pulmonary aspergillosis with a poor prognosis in immunocompr...
Eligibility Criteria
Inclusion
- Inclusion Criteria for the case group (IPA / CPA): :
- Patient who are more than 18 years old
- Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of IPA or CPA in current care. Probable or proven invasive pulmonary aspergillosis according to the criteria of the EORTC (2019).
- Patient who has given his consent.
- Inclusion Criteria In the control group :
- Patient who are more than 18 years old
- Patients for whom bronchial endoscopy with BAL is performed as part of an exploration of diffuse interstitial lung disease or a lower respiratory infection other than Aspergillus in routine care. Chronic pulmonary aspergillosis according to the criteria of ESCMID / ERS (2016)
- Patient who has given his consent.
- Exclusion Criteria for the case and the control group:
- Pregnant woman
- Patient deprived of their rights
- Patient under tutorship or guardianship or under the protection of a conservator
Exclusion
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04728763
Start Date
February 1 2021
End Date
April 1 2021
Last Update
January 28 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.